Patients receiving photodynamic therapy (PDT) with verteporfin (Visudyne®, Novartis AG), a new treatment for subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and pathologic myopia, should be scheduled for follow-up every 12 weeks (±2 weeks) after the initial treatment. However, important data from clinical practice and from small series studies suggest that this period between treatment may be too long for some patients. In this pilot study we explore the safety and the possibility of improving the extent and duration of PDT benefit using feeder vessel treatment (FVT). This study suggests that the combination of verteporfin therapy and FVT is a safe procedure; it also suggests a possibility for prolonging the effect of verteporfin therapy.
- Age-related macular degeneration
- Choroidal neovascularization
- Feeder vessel treatment
- Photodynamic therapy
ASJC Scopus subject areas